Jon joined Advent in 2018 and brings 20+ years of experience from some of the leading biotech companies in the UK.
He has a track record of success in early-stage drug discovery against first in class targets, the application of gene editing to drug discovery, developing new therapeutic technology platforms and in business development, most recently serving as CSO of Horizon Discovery. Since joining Advent, he has concentrated on newco creation, serving first as the founding CEO of Pheno Therapeutics and he is now the founding CEO of cancer immune-therapeutics company Epitopea.
Jon is originally a biochemist and cell biologist with a PhD from the University of Newcastle upon Tyne and extensive postdoctoral experience in academia including 4 years with Nobel Laureate, Tim Hunt.
We use our own and third party cookies that are essential to make our website work. We also use other cookies for analytics on site usage to help us improve our site and give you an easy and personalised experience. You can 'Accept All' other cookies or customise your preferences to reject or permit specific cookies by visiting "Cookie Consent" and selecting "Cookie Settings" in the pop-up at the bottom of the window.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.